Clinica Universidad de Navarra | Sede Madrid - Hematology Department
Status and phase
Conditions
Treatments
About
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Full description
EO2463 Is an innovative cancer peptide therapeutic vaccine based on the homologies between tumor associated antigens and microbiome-derived peptides that will be administered alone and in combination with lenalidomide, rituximab, and lenalidomide/rituximab to generate safety and preliminary efficacy data in patients with indolent NHL
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
60 participants in 4 patient groups
Loading...
Central trial contact
Karlijn Kroon, MD; Jan Fagerberg, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal